Mesenchymal stem cells could be the key to bone regeneration 11 October 2021 | By Anna Begley (Drug Target Review) Scientists have identified a subpopulation of mesenchymal stem cells with enhanced bone fracture healing and differentiation abilities.
Stealth BioTherapeutics reports positive pre-clinical data for ALS candidate 11 October 2021 | By Anna Begley (Drug Target Review) Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
Oral COVID-19 vaccine reduces transmission in animal model 11 October 2021 | By Anna Begley (Drug Target Review) A new study has suggested that mucosal vaccines may reduce transmission of airborne viruses such as COVID-19 more than injectable vaccines.
Pre-clinical trials to test if psychedelic drugs reduce alcohol consumption 8 October 2021 | By Anna Begley (Drug Target Review) Landmark pre-clinical studies to investigate whether psychedelic derivatives can reduce alcohol consumption have been initiated.
Nanobubbles show promise for delivering anti-inflammation treatments 8 October 2021 | By Anna Begley (Drug Target Review) Nanobubbles known as extracellular vesicles (EVs) were shown to deliver protein drugs in animal models with inflammatory diseases.
New drug target identified for myelodysplastic syndrome 8 October 2021 | By Anna Begley (Drug Target Review) Researchers have uncovered how mutations affecting RNA splicing alter cells to develop myelodysplastic syndrome (MDS).
Scientists establish genetic link between HLA and genital warts 7 October 2021 | By Anna Begley (Drug Target Review) The discovery of a link between the human leukocyte antigen (HLA) and genital warts may lead to mRNA-based vaccines against HPV and other diseases.
Small molecule RGX-202 prevents metastasis in colorectal cancer 7 October 2021 | By Anna Begley (Drug Target Review) RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
Chemotherapy drug reverses Alzheimer’s symptoms in mice 7 October 2021 | By Anna Begley (Drug Target Review) Axitinib, a common chemotherapy drug, restored memory and cognitive function in mouse models, representing a potential Alzheimer’s treatment.
Novel “living medicine” could treat antibiotic-resistant infections 6 October 2021 | By Anna Begley (Drug Target Review) Researchers have created the first “living medicine” to treat antibiotic-resistant bacteria growing on the surfaces of medical implants.
UC Riverside granted $5 million for stem cell research training 6 October 2021 | By Anna Begley (Drug Target Review) A $5 million grant will be used to train students in stem cell research to contribute towards new stem cell-based therapeutics.
Two-week-old human embryos reveal origin of Huntington’s disease 6 October 2021 | By Anna Begley (Drug Target Review) Scientists have discovered a signalling pathway alteration in embryos with Huntington’s disease, paving the way for ground-breaking treatments.
New UK coronavirus research and innovation network launched 5 October 2021 | By Anna Begley (Drug Target Review) The UK International Coronavirus Network (UK-ICN) aims to enhance knowledge of the virus family to prepare responses for future outbreaks.
Experimental vaccine a major breakthrough for rheumatoid arthritis 5 October 2021 | By Anna Begley (Drug Target Review) A protein-based vaccine has proven a promising option to prevent rheumatoid arthritis, improving bone quality in animal models.
Psilera to collaborate with NIDA on pre-clinical psychedelic studies 5 October 2021 | By Anna Begley (Drug Target Review) Psilera will participate in two studies with the National Institute on Drug Abuse to combat addiction using a novel DMT formulation.
